Dyne Therapeutics Stock Plunges 23% Despite Upcoming Long-Term Clinical Data

Dyne Therapeutics (DYN) reported 1-year efficacy and safety data from its Phase 1/2 ACHIEVE trial, showing functional gains in myotonic dystrophy type 1. The stock has fallen 37% in 3 months but is up 84% over 3 years. Analysts suggest it's 57% undervalued at $36 per share, citing its FORCE platform's efficiency. Risks include potential trial failures and equity dilution.

Dyne Therapeutics (DYN) shares rose 2.1% after reporting 1-year trial data for DM1 treatment z-basivarsen. The Phase 1/2 ACHIEVE trial showed improvements in functional tests and muscle strength. The company expects topline data in Q1 2027, aiming for U.S. Accelerated Approval submission in Q3 2027. Z-basivarsen showed a favorable safety profile.

Dyne Therapeutics, Inc. (DYN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion o

Dyne Therapeutics (DYN) reported 12-month data from its Phase 1/2 ACHIEVE trial of z-basivarsen for Myotonic Dystrophy Type 1, showing functional improvements across multiple measures. The company expects topline data from the registrational expansion cohort in Q1 2027, with a potential U.S. Accelerated Approval submission in Q3 2027. The mean baseline vHOT in the ACHIEVE REC is 8.3 seconds.

Dyne Therapeutics (DYN) shares dropped 10% after-hours on plans to raise $300M via a stock offering. This follows FDA acceptance of its z-rostudirsen application for Duchenne muscular dystrophy, with a decision expected by January 2027. The company aims to use proceeds for clinical development and commercial infrastructure. DYN stock is up 22% year-to-date.

Novartis (NVS) shares fell 14% after a late-stage trial for del-desiran in myotonic dystrophy type 1 failed its primary test, marking its second trial failure in a week. The drug showed activity on secondary measures, and the company will review data. Dyne Therapeutics (DYN) and Sarepta Therapeutics (SRPT) also declined in sympathy.